Ann Dermatol.  2015 Oct;27(5):641-643. 10.5021/ad.2015.27.5.641.

Imatinib Mesylate-Induced Erythema Multiforme: Recurrence after Rechallenge with 200 mg/day Imatinib

• Lee MK
• Kwon WJ
• Cho EB
• Park EJ
• Kim KH
• Kim KJ

• KMID: 2171478
• DOI: http://doi.org/10.5021/ad.2015.27.5.641

Abstract

No abstract available.

MeSH Terms

Erythema Multiforme*
Erythema*
Recurrence*
Imatinib Mesylate

Figure

• 

  Fig. 1 Clinical manifestations of the patient. (A) Generalized erythematous variable-sized wheal-like patches on the trunk. (B) Several lesions showing the typical targetoid appearance.

• 

  Fig. 2 Histopathological findings of the lesion. (A) Vacuolar degeneration, tagging of lymphocytes along the dermal-epidermal junction, and perivascular lymphocytic and a few eosinophilic infiltrations in the upper dermis (H&E, ×200). (B) Spongiosis and necrotic keratinocytes in the epidermis (H&E, ×400).

Reference

1. Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol. 2003; 48:201–206.

2. Brouard M, Saurat JH. Cutaneous reactions to STI571. N Engl J Med. 2001; 345:618–619.

3. Park HJ, Kim HS, Kim HJ, Lee JY, Cho BK, Lee AW, et al. Immunohistochemical characterization of cutaneous drug eruptions by STI571. J Dermatol Sci. 2005; 38:9–15.

4. Hsiao LT, Chung HM, Lin JT, Chiou TJ, Liu JH, Fan FS, et al. Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol. 2002; 117:620–622.

5. Lee JH, Chung JY, Jung MY, Kim CR, Park JH, Park JH, et al. Lichenoid drug eruption after low-dose imatinib mesylate treatment. Ann Dermatol. 2013; 25:500–502.